Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

79.34USD
21 Feb 2018
Change (% chg)

$1.38 (+1.77%)
Prev Close
$77.96
Open
$77.96
Day's High
$81.36
Day's Low
$77.96
Volume
55,047
Avg. Vol
86,754
52-wk High
$95.64
52-wk Low
$27.53

Select another date:

Wed, Feb 7 2018

BRIEF-Enanta Pharmaceuticals Reports Q1 Earnings Per Share $0.59

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated

* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

BRIEF-Enanta Pharma Q4 earnings per share $1.86

* Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

BRIEF-Enanta Pharmaceuticals announces new data presentations on EDP-305

* Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

BRIEF-Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

* Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

Select another date: